FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308378757> ?p ?o ?g. }

• W4308378757 abstract "<h3>Background</h3> Chimeric antigen receptor T cells (CAR-T) therapy has been applied in the treatment of B cell lymphoma; however, CAR-T manufacturing requires virus or non-virus based genetic modification which causes high manufacturing cost and potential safety concerns. The novel antibody cell conjugation (ACC) technology has the advantage to direct innate immune cells, such as γδ T and NK cells, to find and erase cancer cells by linking cancer-targeting antibodies on cell surface proteins without genetic modification. In this study, ACC technology was applied to generate a novel off-the-shelf CD20-targeting γδ T cell therapy ACE1831, and the potential mechanism of ACC-mediated cytotoxicity was elucidated. <h3>Methods</h3> PBMC-derived γδ T cells were expanded from healthy donors. DNA linker-1 and linker-2 were conjugated to γδ T cells and Rituximab, respectively. Linker-1 conjugated Rituximab was attached to linker-2 conjugated γδ T cells by DNA hybridization to generate off-the-shelf CD20-targeting γδ T cell product, ACE1831. <i>In vitro</i> and <i>in vivo</i> potency of ACE1831 against CD20-expressing cancer cells was evaluated in B cell lymphoma models. Mass spectrometry analysis was performed to identify Rituximab-linked surface proteins of γδ T cells. Jurkat T cells expressing a luciferase reporter driven by an NFAT-response element were used to examine the mechanism of ACC-mediated T cell activation. <h3>Results</h3> ACE1831 exhibited CD20-specific binding activity and viability after recovery from cryopreservation. In vitro cytotoxicity analysis demonstrated the superior potency of ACE1831 against B cell lymphoma including Raji, Rituximab-resistant Raji and Daudi cells, while no significant off-target toxicity against CD20-negative cells or PBMCs was observed. The enhanced secretion of IFNγ and TNFα has been detected when ACE1831 encountered Raji cells, whereas IL-6 remained undetectable. Furthermore, ACE1831 showed excellent in vivo potency in B cell lymphoma xenograft model, and ACE1831-treated mice remained cancer-free to the end of the study. By mass spectrometry analysis, Rituximab-linked proteins were identified, and the protein functions were mainly related to cell activation and immune synapse. Additionally, NFAT signaling was significantly activated when Rituximab-linked Jurkat cells encountered CD20-expressing cancer cells. Blocking TCRγδ activation partially inhibited ACE1831-mediated cytotoxicity, indicating both TCRγδ and external ACC-linked Rituximab involved in ACE1831 potency against B cell lymphoma. <h3>Conclusions</h3> This study provides the evidence for the efficacy and safety of ACE1831 to support the clinical application against CD20-expressing tumors and elucidates the potential mechanism of ACC-mediated activation and cytotoxicity. ACE1831 will be evaluated in clinical trials for relapsed/refractory B cell lymphomas. <h3>Ethics Approval</h3> SCID-Beige mice were purchased and housed under the regulation of the Institutional Animal Care and Use Committee (IACUC) of the contract research organizations." @default.
• W4308378757 created "2022-11-11" @default.
• W4308378757 creator A5010093731 @default.
• W4308378757 creator A5024478289 @default.
• W4308378757 creator A5028795995 @default.
• W4308378757 creator A5029549040 @default.
• W4308378757 creator A5036308308 @default.
• W4308378757 creator A5060090818 @default.
• W4308378757 creator A5067524876 @default.
• W4308378757 creator A5068091095 @default.
• W4308378757 creator A5070313473 @default.
• W4308378757 creator A5072529433 @default.
• W4308378757 creator A5083340557 @default.
• W4308378757 creator A5086728587 @default.
• W4308378757 date "2022-11-01" @default.
• W4308378757 modified "2023-10-06" @default.
• W4308378757 title "251 Application of antibody-cell conjugation technology in a novel off-the-shelf CD20-targeting gamma delta T cell therapy ACE1831" @default.
• W4308378757 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0251" @default.
• W4308378757 hasPublicationYear "2022" @default.
• W4308378757 type Work @default.
• W4308378757 citedByCount "0" @default.
• W4308378757 crossrefType "proceedings-article" @default.
• W4308378757 hasAuthorship W4308378757A5010093731 @default.
• W4308378757 hasAuthorship W4308378757A5024478289 @default.
• W4308378757 hasAuthorship W4308378757A5028795995 @default.
• W4308378757 hasAuthorship W4308378757A5029549040 @default.
• W4308378757 hasAuthorship W4308378757A5036308308 @default.
• W4308378757 hasAuthorship W4308378757A5060090818 @default.
• W4308378757 hasAuthorship W4308378757A5067524876 @default.
• W4308378757 hasAuthorship W4308378757A5068091095 @default.
• W4308378757 hasAuthorship W4308378757A5070313473 @default.
• W4308378757 hasAuthorship W4308378757A5072529433 @default.
• W4308378757 hasAuthorship W4308378757A5083340557 @default.
• W4308378757 hasAuthorship W4308378757A5086728587 @default.
• W4308378757 hasBestOaLocation W43083787571 @default.
• W4308378757 hasConcept C147483822 @default.
• W4308378757 hasConcept C153911025 @default.
• W4308378757 hasConcept C159654299 @default.
• W4308378757 hasConcept C179464577 @default.
• W4308378757 hasConcept C18031839 @default.
• W4308378757 hasConcept C185592680 @default.
• W4308378757 hasConcept C203014093 @default.
• W4308378757 hasConcept C2776090121 @default.
• W4308378757 hasConcept C2777701055 @default.
• W4308378757 hasConcept C2780674031 @default.
• W4308378757 hasConcept C3875195 @default.
• W4308378757 hasConcept C502942594 @default.
• W4308378757 hasConcept C86803240 @default.
• W4308378757 hasConcept C8891405 @default.
• W4308378757 hasConcept C95444343 @default.
• W4308378757 hasConceptScore W4308378757C147483822 @default.
• W4308378757 hasConceptScore W4308378757C153911025 @default.
• W4308378757 hasConceptScore W4308378757C159654299 @default.
• W4308378757 hasConceptScore W4308378757C179464577 @default.
• W4308378757 hasConceptScore W4308378757C18031839 @default.
• W4308378757 hasConceptScore W4308378757C185592680 @default.
• W4308378757 hasConceptScore W4308378757C203014093 @default.
• W4308378757 hasConceptScore W4308378757C2776090121 @default.
• W4308378757 hasConceptScore W4308378757C2777701055 @default.
• W4308378757 hasConceptScore W4308378757C2780674031 @default.
• W4308378757 hasConceptScore W4308378757C3875195 @default.
• W4308378757 hasConceptScore W4308378757C502942594 @default.
• W4308378757 hasConceptScore W4308378757C86803240 @default.
• W4308378757 hasConceptScore W4308378757C8891405 @default.
• W4308378757 hasConceptScore W4308378757C95444343 @default.
• W4308378757 hasLocation W43083787571 @default.
• W4308378757 hasOpenAccess W4308378757 @default.
• W4308378757 hasPrimaryLocation W43083787571 @default.
• W4308378757 hasRelatedWork W1575206612 @default.
• W4308378757 hasRelatedWork W1976133526 @default.
• W4308378757 hasRelatedWork W2499376085 @default.
• W4308378757 hasRelatedWork W2910848452 @default.
• W4308378757 hasRelatedWork W3126318561 @default.
• W4308378757 hasRelatedWork W3134662031 @default.
• W4308378757 hasRelatedWork W3176093986 @default.
• W4308378757 hasRelatedWork W4283161042 @default.
• W4308378757 hasRelatedWork W4283762571 @default.
• W4308378757 hasRelatedWork W4317538414 @default.
• W4308378757 isParatext "false" @default.
• W4308378757 isRetracted "false" @default.
• W4308378757 workType "article" @default.